Skip to main content
main-content

10.08.2019 | Retinal Disorders | Ausgabe 11/2019

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2019

Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial

Zeitschrift:
Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 11/2019
Autoren:
Morteza Entezari, Zahra Kiani Flavarjani, Alireza Ramezani, Humayon Nikkhah, Saeed Karimi, Hamid Fateh Moghadam, Narsis Daftarian, Mehdi Yaseri
Wichtige Hinweise
The work was carried out by Ophthalmic Research Centre Shahid Beheshti University of Medical Sciences.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose

To evaluate the effect of three intravitreal bevacizumab (IVB) injections alone or in combination with intravitreal erythropoietin (EPO) in the treatment of refractory diabetic macular edema (DME).

Methods

In a randomized double-blind clinical trial, 48 eyes of 34 diabetic patients with refractory DME were enrolled. Eyes were randomly assigned to receive either 3 monthly injections of 0.05 cc (1.25 mg) IVB plus 0.05 cc (1000 unit) EPO or 0.05 cc (1.25 mg) IVB alone. Main outcome was best-corrected visual acuity (BCVA) changes and secondary outcome was central macular thickness (CMT). The patients were followed for 6 months.

Results

Mean BCVA changes up to 4 and 6 months were insignificant in both groups. It changed from 0.72 ± 0.56 logMAR at baseline to 0.74 ± 0.5 (P = 0.85) and 0.71 ± 0.44 (P = 0.40) in the combination group and from 0.48 ± 0.39 logMAR to 0.47 ± 0.35 (P = 0.48) and 0.52 ± 0.33 (P = 0.69) in the IVB alone group, at 4 and 6 months, respectively. The difference of mean BCVA changes between the groups was insignificant at both 4 and 6 months (P = 0.07 and P = 0.36, respectively). Within the group changes of mean CMT were significant only in the combination group at 4 and 6 months, from 518 ± 134 μ at baseline to 472 ± 151 to 475 ± 167 μ, respectively (P = 0.01 and P = 0.05). Corresponding changes were not significant in the IVB alone group. However, the difference between the groups was not significant at all visits (P = 0.51 and P = 0.71, respectively).

Conclusions

This clinical trial demonstrated that intravitreal erythropoietin had no additional effect to IVB in the treatment of refractory DME in the short term.

Trial registration

Clinical trials.gov identifier: NCT03821168

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med bestellen und 100 € sparen!

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2019

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2019 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

29.01.2020 | DFP-Fortbildung | Ausgabe 1/2020

„White-dot-Syndrome“

Grundlagen, Diagnostik und Therapie

08.01.2020 | Erkrankungen der Hornhaut | CME | Ausgabe 1/2020

Anteriore virale Uveitis

Klinik, diagnostisches Vorgehen und Behandlungsoptionen